|
C11orf95
|
0.500 |
Biomarker
|
disease |
BEFREE |
A subgroup of supratentorial ependymomas are characterized by C11orf95-RELA fusions, presumed to be secondary to chromothripsis of chromosome 11, resulting in constitutive activation of the NF-κB signaling pathway and overexpression of cyclin D1, p65, and L1 cell adhesion molecule (L1CAM).
|
31375768 |
2020 |
|
C11orf95
|
0.500 |
Biomarker
|
disease |
BEFREE |
Here, we have used interphase fluorescent in situ hybridization (FISH) for C11orf95 and RELA, immunohistochemistry (IHC) for p65-RelA and the recently developed DNA methylation-based classification besides conventional histopathology, and compared the precision of the methods in 40 supratentorial pediatric brain tumors diagnosed as ependymomas in the past years.
|
30325077 |
2019 |
|
C11orf95
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recent advances in the molecular classification of EPN revealed a supratentorial (ST) ependymoma subgroup characterized by C11orf95-RELA fusion.
|
30631904 |
2019 |
|
C11orf95
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although most CEs in our group were immunopositive for L1CAM and showed C11orf95-RELA fusion, which have been associated with a poor prognosis in supratentorial ependymomas, all our patients had good outcomes.
|
31150846 |
2019 |
|
C11orf95
|
0.500 |
Biomarker
|
disease |
BEFREE |
Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.
|
30514397 |
2018 |
|
C11orf95
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The majority of supratentorial ependymomas (ST-ependymomas) have few mutations but frequently display chromothripsis of chromosome 11q that generates a fusion between C11orf95 and RELA (RELA<sup>FUS</sup>).
|
29949764 |
2018 |
|
C11orf95
|
0.500 |
Biomarker
|
disease |
BEFREE |
Clinicopathological features of ST-EPNs in correlation with C11orf95-RELA and YAP1 fusions have been assessed in only few studies.
|
29354850 |
2018 |
|
C11orf95
|
0.500 |
Biomarker
|
disease |
BEFREE |
A novel recurrent oncogenic fusion involving the C11orf95 and RELA genes was recently described in supratentorial ependymomas.
|
27121356 |
2016 |
|
C11orf95
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
They are supratentorial ependymomas with C11orf95-RELA fusion or YAP1 fusion, infratentorial ependymomas with or without a hypermethylated phenotype (CIMP), and spinal cord ependymomas.
|
27022130 |
2016 |
|
C11orf95
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We here describe a case of a sarcoma developing in a patient previously treated with chemotherapy and radiation whose original ependymoma and recurrent sarcoma were both shown to carry the type 1 C11orf95-RELA fusion transcript indicating a monoclonal origin for both tumors.
|
25388523 |
2015 |
|
C11orf95
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although no recurrently mutated genes were found throughout these groups of ependymomas, PFA exhibited a CpG island methylator phenotype, PFB was associated with extensive chromosomal aberrations, and the C11orf95-RELA fusion gene was frequently observed in supratentorial ependymomas.
|
25182241 |
2014 |
|
C11orf95
|
0.500 |
Biomarker
|
disease |
BEFREE |
C11orf95-RELA fusion proteins translocated spontaneously to the nucleus to activate NF-κB target genes, and rapidly transformed neural stem cells--the cell of origin of ependymoma--to form these tumours in mice.
|
24553141 |
2014 |
|
C11orf95
|
0.500 |
FusionGene
|
disease |
ORPHANET |
Our data identify a highly recurrent genetic alteration of RELA in human cancer, and the C11orf95-RELA fusion protein as a potential therapeutic target in supratentorial ependymoma.
|
24553141 |
2014 |
|
C11orf95
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|